Infantile fibrosarcoma treated with postoperative vincristine and dactinomycin

Pediatr Int. 2017 Mar;59(3):371-374. doi: 10.1111/ped.13229.

Abstract

Infantile fibrosarcoma is a non-rhabdomyosarcoma soft-tissue sarcoma that occurs in infancy and which has a relatively good prognosis. A vincristine and dactinomycin (VA) regimen has been shown to be effective, although the duration of chemotherapy has not been well defined. We describe the case of a 4-month-old boy with a mass at the left dorsum of the foot who was diagnosed with infantile fibrosarcoma after resection of the tumor, the margin of which was macroscopically positive. VA treatment was carried out with careful monitoring of response and adverse effects. Pancytopenia was seen during the second cycle, and therapy was reduced thereafter. The treatment was continued for 38 weeks (12 cycles). There was no functional impairment, and no evidence of recurrence at 18 months after therapy.

Keywords: adjuvant chemotherapy; dactinomycin; fibrosarcoma; infant; vincristine.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Adjuvant
  • Dactinomycin / therapeutic use*
  • Fibrosarcoma / drug therapy*
  • Fibrosarcoma / surgery
  • Foot / surgery*
  • Humans
  • Infant
  • Male
  • Soft Tissue Neoplasms / drug therapy*
  • Soft Tissue Neoplasms / surgery
  • Vincristine / therapeutic use*

Substances

  • Antineoplastic Agents
  • Dactinomycin
  • Vincristine